Amneal Pharmaceuticals Management
Management criteria checks 4/4
Amneal Pharmaceuticals' CEO is Chirag Patel, appointed in Jan 2005, has a tenure of 19.33 years. total yearly compensation is $2.37M, comprised of 31.6% salary and 68.4% bonuses, including company stock and options. directly owns 7.06% of the company’s shares, worth $131.78M. The average tenure of the management team and the board of directors is 4.8 years and 6 years respectively.
Key information
Chirag Patel
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 31.6% |
| CEO tenure | 19.3yrs |
| CEO ownership | 7.1% |
| Management average tenure | 4.8yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31Amneal Pharmaceuticals Q2 2022 Earnings Preview
Aug 04Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of Debt
Apr 16Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management
Mar 30Revisiting Amneal Pharmaceuticals After Its CEO Buys Shares
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
| Sep 30 2019 | n/a | n/a | -US$339m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$325k | n/a | -US$21m |
Compensation vs Market: Chirag's total compensation ($USD2.37M) is below average for companies of similar size in the US market ($USD5.72M).
Compensation vs Earnings: Chirag's compensation has been consistent with company performance over the past year.
CEO
Chirag Patel (56 yo)
19.3yrs
Tenure
US$2,370,385
Compensation
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.3yrs | US$2.37m | 7.06% $ 131.8m | |
| Co-Founder | 22.3yrs | US$2.37m | 8.19% $ 152.9m | |
| Executive VP & CFO | 4.2yrs | US$1.89m | 0.17% $ 3.2m | |
| Senior VP | 2.3yrs | US$1.35m | 0.019% $ 346.8k | |
| Executive VP & Chief Human Resources Officer | 10.3yrs | US$1.53m | 0.13% $ 2.4m | |
| Executive VP & Chief Commercial Officer of Generics | 6.3yrs | US$1.94m | 0.10% $ 1.9m | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | 1.3yrs | no data | no data | |
| Senior VP of Strategic Sourcing & Supply Management | 1.3yrs | no data | no data | |
| Chief Quality Officer | 5.3yrs | no data | no data | |
| Senior VP & Chief Scientific Officer of Generics | 4.3yrs | no data | no data | |
| Vice President & Head of Medical Affairs | no data | no data | no data |
4.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: AMRX's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.3yrs | US$2.37m | 7.06% $ 131.8m | |
| Co-Founder | 22.3yrs | US$2.37m | 8.19% $ 152.9m | |
| Independent Chairman of the Board | 4.8yrs | US$299.08k | 0.20% $ 3.8m | |
| Independent Director | 6yrs | US$302.20k | 0.060% $ 1.1m | |
| Independent Director | 6yrs | US$244.70k | 0.073% $ 1.4m | |
| Independent Director | 4.4yrs | US$254.70k | 0.055% $ 1.0m | |
| Independent Director | 4.4yrs | US$277.20k | 0.063% $ 1.2m | |
| Director | 6yrs | US$217.20k | 0.63% $ 11.7m | |
| Independent Director | 1.8yrs | US$267.04k | 0.018% $ 332.5k | |
| Independent Director | 6yrs | US$217.20k | 0.057% $ 1.1m | |
| Independent Director | 4.4yrs | US$284.70k | 0.058% $ 1.1m |
6.0yrs
Average Tenure
56yo
Average Age
Experienced Board: AMRX's board of directors are considered experienced (6 years average tenure).